Abbott realtime MTB assay for detecting Mycobacterium tuberculosis complex in respiratory specimens: a cost-benefit analysis
Authors:
- 3 July 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (9) , 1699-1709
Abstract
Purpose Molecular screening for Mycobacterium tuberculosis (MTB) can lead to rapid empirical treatment inception and reduce hospitalization time and complementary diagnostic tests. However, in low-prevalence settings, the cost-benefit balance remains controversial due to the high cost. Methods We used a Markov model to perform an economic analysis to evaluate the profit after implementing molecular MTB screening (Period B) compared with conventional culture testing (Period A) in respiratory samples from 7,452 consecutive subjects with presumed tuberculosis (TB). Results The proportion of positivity was comparable between both periods (P > 0.05), with a total of 2.16 and 1.78 samples/patient requested in periods A and B, respectively (P < 0.001). The mean length of hospital stay was 8.66 days (95%CI: 7.63–9.70) in Period B and 11.51 days (95%CI: 10.15–12.87) in Period A (P = 0.001). The healthcare costs associated with diagnosing patients with presumed TB were reduced by €717.95 per patient with PCR screening. The probability of remaining hospitalized and the need for a greater number of outpatient specialty care visits were the variables with the most weight in the model. Conclusion Employing PCR as an MTB screening method in a low-prevalence setting may increase the profits to the system.Keywords
This publication has 18 references indexed in Scilit:
- Revisiting the methods for detecting Mycobacterium tuberculosis: what has the new millennium brought thus far?Access Microbiology, 2021
- Evaluation of screening strategies for pulmonary tuberculosis among hospitalized patients in a low-burden setting: cost-effectiveness of GeneXpert MTB/RIF compared to smear microscopyInfection Control & Hospital Epidemiology, 2021
- Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosisCochrane Database of Systematic Reviews, 2021
- Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention StudyJournal of Clinical Microbiology, 2018
- Clinical evaluation of the Abbott RealTi me MTB Assay for direct detection of Mycobacterium tuberculosis -complex from respiratory and non-respiratory samplesTuberculosis, 2017
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and ChildrenClinical Infectious Diseases, 2017
- The Point-of-Care Laboratory in Clinical MicrobiologyClinical Microbiology Reviews, 2016
- Performance characteristics of the new Abbott Real Time MTB assay for detection of Mycobacterium tuberculosis complex in respiratory specimensDiagnostic Microbiology and Infectious Disease, 2016
- Performance of the new automated Abbott RealTime MTB assay for rapid detection of Mycobacterium tuberculosis complex in respiratory specimensEuropean Journal of Clinical Microbiology & Infectious Diseases, 2015
- Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosisEnfermedades Infecciosas y Microbiología Clínica, 2010